Scientists in China have developed an experimental gene-editing therapy that significantly reduced "bad" cholesterol levels in patients with a rare genetic condition known as familial hypercholesterolemia. In a small clinical trial involving six volunteers aged 34 to 62, the treatment led to a 52% decrease in low-density lipoprotein cholesterol (LDL-C), the type of cholesterol linked to heart disease. This condition causes the body to struggle with removing excess cholesterol from the bloodstream, leading to dangerously high levels. The therapy works by targeting the PCSK9 gene in the liver, which plays a role in regulating how the liver removes LDL-C. When this gene is overactive, it can hinder the removal of bad cholesterol. To address this, Chinese researchers modified an enzyme from a bacterium called Hafnia paralvei to precisely edit the PCSK9 gene in liver cells. Three participants who received the highest dose of the therapy experienced a 74% reduction in PCSK9 enzyme activity, suggesting the treatment may be highly effective. While the results are promising, some participants reported mild side effects such as fever and muscle aches, which subsided within 24 hours. No severe adverse events were reported. Researchers plan to monitor the patients for up to 15 years to assess the long-term safety and effectiveness of the treatment. This study represents a significant step forward in the use of gene-editing techniques for treating lipid disorders. In a separate trial conducted by the Cleveland Clinic in the United States, scientists tested a similar gene-editing approach targeting the ANGPTL3 gene. Four participants in this trial saw their LDL-C levels drop by 52% and their triglycerides—another type of fat in the blood—fall by 48%. These findings suggest that gene-editing therapies could be a powerful new tool in treating a range of lipid-related conditions, potentially offering long-term solutions for patients who struggle with traditional cholesterol-lowering medications.